RECRO PHARMA INC (REPH)

Common Stock

2.09  -0.01 (-0.48%)

After market: 2.09 0 (0%)

Fundamental Rating

1

REPH gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 197 industry peers in the Pharmaceuticals industry. REPH has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, REPH is valued expensive at the moment.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

REPH had negative earnings in the past year.
REPH had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: REPH reported negative operating cash flow in multiple years.

1.2 Ratios

Industry RankSector Rank
ROA -7.09%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM 0.55%
PM (TTM) -15.09%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for REPH has been increased compared to 1 year ago.
Compared to 1 year ago, REPH has an improved debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -0.81, we must say that REPH is in the distress zone and has some risk of bankruptcy.
REPH has a Debt/Equity ratio of 2.27. This is a high value indicating a heavy dependency on external financing.
Industry RankSector Rank
Debt/Equity 2.27
Debt/FCF N/A
Altman-Z -0.81
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 3.24 indicates that REPH has no problem at all paying its short term obligations.
A Quick Ratio of 2.74 indicates that REPH has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 3.24
Quick Ratio 2.74

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 73.04% over the past year.
Looking at the last year, REPH shows a quite strong growth in Revenue. The Revenue has grown by 13.32% in the last year.
REPH shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.68% yearly.
EPS 1Y (TTM)73.04%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q91.67%
Revenue 1Y (TTM)13.32%
Revenue growth 3Y-0.87%
Revenue growth 5Y1.68%
Revenue growth Q2Q125.06%

3.2 Future

Based on estimates for the next years, REPH will show a small growth in Earnings Per Share. The EPS will grow by 1.18% on average per year.
REPH is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.49% yearly.
EPS Next Y5.68%
EPS Next 2Y10.01%
EPS Next 3Y4.51%
EPS Next 5Y1.18%
Revenue Next Year22.76%
Revenue Next 2Y15.97%
Revenue Next 3Y15.26%
Revenue Next 5Y15.49%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

REPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for REPH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 21.28

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.01%
EPS Next 3Y4.51%

More info and screens

0

5. Dividend

5.1 Amount

REPH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RECRO PHARMA INC

NASDAQ:REPH (3/21/2022, 8:00:01 PM)

After market: 2.09 0 (0%)

2.09

-0.01 (-0.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap97.56M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.09%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM 0.55%
PM (TTM) -15.09%
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 2.27
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 3.24
Quick Ratio 2.74
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)73.04%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y5.68%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)13.32%
Revenue growth 3Y-0.87%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y